Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This study will determine the maximum-tolerated dose (MTD) for oral bosutinib when used in
combination with pemetrexed. The MTD is the highest dose of bosutinib with pemetrexed that
can be given without causing severe side effects. This study will also test the safety of
this combination and see what effects (good or bad) it has on participants and their cancer.